Can Fite Biopharma Ltd ADR

Yahoo Finance • 8 hours ago

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: UiPath Inc.(NYSE:PATH) shares gained in extended trading on Tuesday after it was announced tha... Full story

Yahoo Finance • 22 hours ago

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction

RAMAT GAN, Israel, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory dis... Full story

Yahoo Finance • 3 days ago

Can-Fite BioPharma approves 1-for-3,000 reverse share split; shares down

* Can-Fite BioPharma’s (CANF [https://seekingalpha.com/symbol/CANF]) board approved a 1-for-3,000 reverse split [https://seekingalpha.com/pr/20348629-can-fite-announces-reverse-split-of-its-ordinary-shares-and-ads-ratio-change] of its or... Full story

Yahoo Finance • 11 days ago

Can-Fite Provides Update on Clinical and Financial Status

RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory dis... Full story

Yahoo Finance • 4 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory dis... Full story

Yahoo Finance • 5 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone

Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology... Full story

Yahoo Finance • 5 months ago

Top movers in Monday's session

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. [topmovers] GAINERS TICKER CHANGE COMMENT CREV [https://www.chartmill.com/stock/quote/CREV/profile] 59.27% E... Full story

Yahoo Finance • 5 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE Americ... Full story

Yahoo Finance • 5 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia

Ramat Gan, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cance... Full story

Yahoo Finance • 5 months ago

Can-Fite BioPharma launches best-efforts offering of ADSs and warrants

* Can-Fite BioPharma (NYSE:CANF [https://seekingalpha.com/symbol/CANF]) is offering up to 4.9 million ADSs (representing 1.47 billion ordinary shares) and 4.9 million common warrants in a best-efforts offering. * Each ADS will be sold... Full story